Literature DB >> 36267705

Identification of key genes and pathway related to chemoresistance of small cell lung cancer through an integrative bioinformatics analysis.

Fan-Rui Zeng1, Xu-Yang Zhou2, Ling-Ge Zeng2, Jian-Cong Sun1, Fen He1, Wei Mo1, Yang Wen2, Shu-Yu Wang2, Qin Liu3, Lin-Lang Guo2.   

Abstract

Background: Small cell lung cancer (SCLC), the most malignant of all the lung cancer subtypes, is characterized by drug resistance. This study sought to explore the key genes and pathways associated with the chemoresistance of SCLC.
Methods: The drug sensitivity of chemosensitive and chemoresistance SCLC cell lines was measured by Cell Counting Kit-8 assays. The total RNA from chemosensitive cell line H69 and chemoresistance cell line H69AR cells was extracted and subjected to messenger RNA (mRNA) and long non-coding RNA (lncRNA) microarray analyses. The differentially expressed genes (DEGs) and the differentially expressed lncRNAs (DELs) were screened out with a threshold of a |log fold change | ≥1 and an adjusted P value <0.05. A protein-protein interaction network was constructed, and hub genes were screened out. A lncRNA-mRNA co-expression network was also constructed. Gene Ontology and Kyoto Encyclopedia of Genes, Genomes enrichment analyses and Cis-regulatory element analyses were conducted on the DEGs and the top 10 upregulated DEL-co-expressed DEGs. The expression of the key genes was further analyzed in the GSE149507 data set and validated in H69/H69AR and H446/H446DDP cells by quantitative polymerase chain reaction assays.
Results: The microarray results showed that a total of 609 mRNAs and 394 lncRNAs were differentially expressed in the chemoresistant SCLC cells. The mammalian target of rapamycin (mTOR) signaling pathway was enriched among the DEGs, the top 10 upregulated DEL-co-expressed DEGs, and the NCRNA00173-co-expressed DEGs, which included IGF1, INS, WNT6, WNT11, WNT2B, and SESN2. IGF1, WNT2B, and SESN2 were downregulated, and WNT11 was upregulated in the SCLC tumor tissues in the GSE149507 data set. Further, IGF1, WNT6, WNT11, and WNT2B were lowlier expressed and SESN2 and NCRNA00173 were more highly expressed in the chemoresistant cells than sensitive cells. Conclusions: The top 10 upregulated DELs containing NCRNA00173 may be involved in the regulation of drug resistance in SCLC. These DELs may regulate the genes related to the mTOR signaling pathway. These genes may also be biomarkers and potential targets for the treatment of SCLC. 2022 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Small cell lung cancer (SCLC); chemoresistance; long non-coding RNA (lncRNA); mTOR pathway; microarray analysis

Year:  2022        PMID: 36267705      PMCID: PMC9577795          DOI: 10.21037/atm-22-3642

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  45 in total

1.  Biological functions of long noncoding RNAs and circular RNAs in small-cell lung cancer.

Authors:  Sachin Kumar; Monu Pandey; Surender K Sharawat
Journal:  Epigenomics       Date:  2020-10-19       Impact factor: 4.778

2.  Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.

Authors:  Haibo Wang; Xianyang Zhang; Irving Vidaurre; Renzhi Cai; Wei Sha; Andrew V Schally
Journal:  Int J Cancer       Date:  2018-03-01       Impact factor: 7.396

Review 3.  Cellular and metabolic functions for autophagy in cancer cells.

Authors:  Candia M Kenific; Jayanta Debnath
Journal:  Trends Cell Biol       Date:  2014-09-30       Impact factor: 20.808

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers.

Authors:  Dong Xie; Randolph Marks; Mingrui Zhang; Gening Jiang; Aminah Jatoi; Yolanda I Garces; Aaron Mansfield; Julian Molina; Ping Yang
Journal:  J Thorac Oncol       Date:  2015-08       Impact factor: 15.609

6.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

Review 7.  The role of long noncoding RNAs in cancer: the dark matter matters.

Authors:  Xiaowen Hu; Anil K Sood; Chi V Dang; Lin Zhang
Journal:  Curr Opin Genet Dev       Date:  2017-10-17       Impact factor: 5.578

Review 8.  Treatment advances in small cell lung cancer (SCLC).

Authors:  Saiama N Waqar; Daniel Morgensztern
Journal:  Pharmacol Ther       Date:  2017-06-01       Impact factor: 12.310

9.  Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.

Authors:  Alex H Wagner; Siddhartha Devarakonda; Zachary L Skidmore; Kilannin Krysiak; Avinash Ramu; Lee Trani; Jason Kunisaki; Ashiq Masood; Saiama N Waqar; Nicholas C Spies; Daniel Morgensztern; Jason Waligorski; Jennifer Ponce; Robert S Fulton; Leonard B Maggi; Jason D Weber; Mark A Watson; Christopher J O'Conor; Jon H Ritter; Rachelle R Olsen; Haixia Cheng; Anandaroop Mukhopadhyay; Ismail Can; Melissa H Cessna; Trudy G Oliver; Elaine R Mardis; Richard K Wilson; Malachi Griffith; Obi L Griffith; Ramaswamy Govindan
Journal:  Nat Commun       Date:  2018-09-17       Impact factor: 14.919

Review 10.  Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.

Authors:  Ildiko Krencz; Daniel Sztankovics; Titanilla Danko; Anna Sebestyen; Andras Khoor
Journal:  Cancer Metastasis Rev       Date:  2021-12-27       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.